Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.
Ryosuke KumanishiShigenori KadowakiSeiichiro MitaniTomohiro MatsushimaTakatsugu OgataYukiya NaritaToshiki MasuishiHideaki BandoMasahiro TajikaHisateru YasuiHiroki HaraKei MuroPublished in: International journal of clinical oncology (2023)
Although no remarkable differences in efficacy were found between IRI and NIVO for AGC, NIVO had a better safety profile compared to IRI. We found no clinical markers that can assist treatment decisions.